Ogilvy Public Relations Worldwide and Shire Health Group have merged part of their operations to form Fast4wD Ogilvy, a clinical …
Re-importation of cheaper medicines from Canada and other countries into the US looks certain to be legalised after the Bush …
The soon to be created Sanofi-Aventis will be dominated by executives from Sanofi-Synthelabo who have pledged to deliver "swift integration" …
GlaxoSmithKline has announced it is to make data from all of its trials available online in an effort to counter …
Contract research organisations (CRO) have benefited from the pressure on the pharmaceutical industry to maintain a flow of blockbusters at …
A new study has found that both oestrogen-only and oestrogen plus progestogen hormone replacement therapies may increase the risk of …
Raptiva, a new psoriasis treatment to be marketed by Serono in Europe has gained a positive opinion from the EMEA.The …
AstraZeneca's new oral anticoagulant Exanta has been launched in Germany, its first global market.The drug is the first in a …
In a world of constant change, why have many pharma companies stuck to traditional organisational structures? Are they really the …
German pharmaceutical company Schering AG will no longer conduct research and development into cardiovascular or, with a few exceptions, central …
The government has promised to eliminate persistent variations in access to cancer drugs across England and Wales, and has unveiled …
The government's drive to transform pharmacists into leading frontline healthcare professionals is to be spearheaded by a new consortium of …
Cocaine addicts could be helped by a vaccine currently in development by UK biotech company Xenova, phase II results from …
Chicago-based Abbott Laboratories has bought the marketing and manufacturing rights for cardiovascular drug trandolapril from Aventis, in a deal worth …
Abilify, Bristol-Myers Squibb and Otsuka's antipsychotic has received European Union marketing approval and will be promoted for having fewer side …
New Lipitor data suggests the drug cut the risk of stroke by half in diabetes patients, the compelling evidence potentially …